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Abstract
Background:  Propranolol, as a beta-adrenergic blocker is used for 
treatment of a large number of cardiovascular diseases such as hy-
pertension and arrhythmias. The inhibitory effects of propranolol 
on tumor cells growth and also its cytotoxicity on cancerous cells 
have been revealed by several studies. In this study the sensitivity 
of a number of human leukemic cell lines to propranolol was evalu-
ated in vitro.
Methods:  Two human leukemic T cells (Molt-4 and Jurkat) and a 
monocyte (U937) cell line were used in this study. The cells were 
cultured in complete RPMI medium and then incubated with differ-
ent concentrations of propranolol (0.0004 -0.4 mM) in the presence 
or absence of phytoheamagglutinin (20 µg/ml) for 12, 24 and 48 
hours. The cytotoxic effect of the drug was then assessed by trypan 
blue dye exclusion and also 3-[4,5-dimethyl thiazol-2,5-diphenyl-
tetrazoliumbromide] (MTT) reduction methods.
Results:  Propranolol induced a significant dose dependent cyto-
toxic effect at ≥ 0.2 mM concentration on all three human cell lines 
(Molt-4, Jurkat and U937) used in this study, after 12 hours incuba-
tion onwards, compared to untreated control cells.
Conclusions:  Our results demonstrated that leukemic cell lines 
used in this study were sensitive to propranolol at ≥ 0.2 mM con-
centration of the drug. These results suggest that propranolol may 
have potential implication in chemoprevention of lymphoprolif-
erative disorders along with its chronic long-term usage in cardiac 
problems.
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Introduction
  Propranolol, as a non selective beta-adrenergic blocker, 
has been extensively used for treatment of many cardiovas-
cular problems such as hypertension and arrhythmias [1, 2]. 
It has been recently suggested that beta-blockers decrease 
tumor progression through suppression of cancerous cells 
proliferation,  inhibition  of  growth  factor  production  and 
apoptosis induction of tumor cells [3]. The inhibitory effect 
of propranolol on phospholipase D pathway, through blocker 
mechanism, resulting in decreased phosphatidic acid (PA) 
production has been shown [4, 5]. PA is a necessary compo-
nent for phospholipids biosynthesis and tumor cell growth 
[5].  Propranolol  inhibitory  effects  on  a  tobacco-induced 
pulmonary adenocarcinoma development [6], uterine leio-
myoma induction [7], human lung adenocarcinoma cell line 
proliferation [8], surgery increased lung tumor retention [3] 
and TNF- alpha induced proliferation of rat C6 glioma cells 
[9] have been reported. In addition, the cytotoxic effects of 
propranolol on rat and human lung cells [10], human skin 
keratinocytes, fibroblasts, corneal and retinal epithelial cell 
lines [11] and also tumor cells have been revealed [5]. More-
over increase in splenocyte apoptosis rate and decrease of 
proliferative capacity of splenocytes after administration of 
propranolol in septic mice has been demonstrated [12, 13]. 
Furthermore anti-inflammatory effects of chronic exposure 
to beta-blockers have been reported [14, 15]. Besides the 
attenuating effect of propranolol on proinflammatory cyto-
kines such as IL-1 beta mRNA expression [16] and TNF-
alpha serum level in migraine patients has been shown [17]. 
  Based on the anti tumor and anti-inflammatory proper-
ties of propranolol, the present study was conducted to ex-
amine the sensitivities of three human leukemic cell lines to 
propranolol in vitro.
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Materials and Methods
 Reagents
  RPMI-1640 medium, penicillin, streptomycin, phyto-
heamagglutinin (PHA), and trypan blue (TB) were purchased 
from Sigma (USA). Fetal calf serum (FCS) was obtained 
from Gibco (USA) and MTT (3-[4,5-dimethyl thiazol-2,5-
diphenyltetrazoliumbromide]) kit was purchased from invit-
rogen (USA). Propranolol was a kind gift from HAKIM Pvt. 
Co. Ltd (Tehran, Iran). Microtiter plates, flasks and tubes 
were purchased from Nunc (Falcon, USA). 
Preparation of propranolol 
   Propranolol was dissolved in RPMI-1640 medium and 
stored at -20°C until use. Drug was diluted in culture me-
dium to prepare appropriate concentrations before use.
Cell lines
  Human leukemic T cells [Molt-4 (NCBI C149) and Jur-
kat (NCBI C121)] and monocyte [U937 (NCBI C130)], were 
obtained from NCBI (National Cell Bank of Iran, Pasteur 
Inst. of Iran, Tehran). The cells were maintained in RPMI-
1640 medium supplemented with 10% FCS in 5% CO2 at 
37°C.
Cell culture and treatment
 Human leukemic cells were cultured in RPMI-1640 me-
dium supplemented with 10% FCS, penicillin (100 IU/ml) 
and streptomycin (100 µg/ml) at 37°C in 5% CO2. The cells 
were seeded at a density of 3 × 104 cell/well and then incu-
bated with different concentrations of propranolol (0.0004 
- 0.4 mM) in the presence or absence of PHA (20 µg/ml) for 
12, 24 and 48 hours. All experiments were done in triplicate. 
Figure 1. Effect of propranolol on proliferative responses of human leukemic Molt-4 T-cell line. The Molt-4 cells were treated with different 
concentrations of  propranolol (0.0004 - 0.4 mM) for 12, 24 and 48 hours. The results are presented as % of viability demonstrated by trypan 
blue dye exclusion (TB) test (A) and cell number/control demonstrated  by MTT assay (B). Data are mean ± SD of triplicate cultures. n = 3;     
P < 0.05 was considered significant.
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Cell proliferation assay
  To evaluate the effect of different concentrations of 
drug on viability of leukemic cell lines, we used trypan blue 
dye exclusion (TB test) [18] and MTT assay [19].
Trypan blue dye exclusion test
   Principle of trypan blue dye exclusion test is exclusion 
of dye by viable cells and taking it up by dead cells. Viability 
is evaluated by direct counting of viable and dead cells. Per-
centage of the number of viable cells to the total number of 
cells is considered as viability percentage. 
MTT assay
 In MTT test the conversion of yellow water soluble 
MTT to a blue-insoluble formazon was assessed according 
to the method developed by Mosmann [19]. At the end of 
incubation time, the medium was replaced with 100 µl of 
fresh medium. The amount of 10 µl of MTT solution (5 mg/
ml in PBS) was then added to each well and incubated at 
37°C for 4 hours. Subsequently 100 µl of the SDS-HCl solu-
tion (100 mg SDS was dissolved in 1 ml HCl) was added to 
each well and incubated at 37°C for 4 hours. So the insoluble 
formazon derivative was dissolved and absorbance at 570 
nm was measured using a microplate reader (Awarness Tech-
nology INC). The results were expressed as cell numbers per 
control. 
Statistical analysis
 Effect of the drug on each cell line was performed in 
three independent experiments (n = 3) and the results were 
expressed as mean ± SD. Statistical comparisons between 
groups were made by analysis of variance (ANOVA). P < 
Figure 2. Effect of propranolol on proliferative responses of human leukemic Jurkat  T-cell line. The Jurkat cells were treated with differ-
ent concentrations of propranolol (0.0004 - 0.4 mM) for 12, 24 and 48 hours. The results are presented as % of viability demonstrated by 
trypan blue dye exclusion (TB) test (A) and cell number/control demonstrated  by MTT assay (B). Data are mean ± SD of triplicate cultures. 
n = 3;  P < 0.05 was considered significant.
146                                                                                                                                                 147J Clin Med Res  •   2009;1(3):144-149 Hajighasemi et al
Articles © The authors, Journal compilation © J of Clin Med Res and Elmer Press™, www.jocmr.org
0.05 was considered significant. Test of multiple comparison 
of Tukey was applied (5%) for statistically significant differ-
ences. For statistical analysis and graph making the software 
SPSS 16.0 and Excel 2003 were used respectively.
 
Results
  Cytotoxic effect of propranolol on human leukemic 
cell lines in different concentrations and time intervals are 
shown in figures 1, 2 and 3. In each figure, “A and B” repre-
sent the results of trypan blue dye exclusion and MTT assays 
respectively. Propranolol significantly decreased prolifera-
tive responses of human leukemic cell lines in both staining 
methods in all time intervals dose-dependently (P < 0.05) 
(Fig. 1-3). The results depicted in Figure 1(A and B) showed 
that propranolol significantly decreased the proliferation of 
Molt-4 cells at ≥ 0.2 mM concentration after 12 hours incu-
bation compared with untreated control cells (P < 0.05).
  According to figure 2(A and B), propranolol signifi-
cantly inhibited proliferation of Jurkat cells at ≥ 0.2 mM pro-
pranolol concentration after 12 hours incubation compared 
with untreated control cells (P <  0.05 ).
  The results illustrated in figure 3(A and B) showed that 
incubation of U937 cells with propranolol led to significant 
inhibition of cell proliferation at ≥ 0.2 mM concentration (P 
< 0.05 ) after 12 hours incubation compared with untreated 
control cells.
   Propranolol cytotoxicity at 0.2 mM concentration was 
significantly increased with time in this order: 48h > 24 h > 
12 h in all cell lines (Fig. 1- 3). Similar results were obtained 
after stimulation of propranolol treated cells with PHA (data 
Figure 3. Effect of propranolol on proliferative responses of human leukemic U937 cell line. The U937 cells were treated with differ-
ent concentrations of propranolol (0.0004 - 0.4 mM) for 12, 24 and 48 hours. The results are presented as % of viability demonstrated 
by trypan blue dye exclusion (TB) test (A) and cell number/control demonstrated  by MTT assay (B). Data are mean ± SD of triplicate 
cultures. n = 3;  P < 0.05 was considered significant.
146                                                                                                                                                 147J Clin Med Res  •  2009;1(3):144-149    Leukemia Cells Sensitivity to Propranolol





 This study was carried out to determine the effects of 
propranolol on proliferative response of human leukemic T 
and monocyte cell lines. Our results demonstrated that all 
three cell lines used in this study were sensitive to propran-
olol after 12 hours incubation time onwards at ≥ 0.2 mM 
drug  concentration  (Fig.  1-3).  So  sensitivity  of  different 
leukemic cell lines was similar to each other indicating that 
toxic mechanism is not cell specific. Similarly Cheong et al 
[11] reported just little differences in toxicity of a number 
of beta-blockers including propranolol on human epithelial 
cell lines, epidermal keratinocytes and dermal fibroblasts for 
each drug. Conversly,  Kastelova et al [10] showed propran-
olol cytotoxicity at different (0.001- 1 mM) concentrations 
in rat and human alveolar macrophages, rat type II pneumo-
cytes and human lung adenocarcinoma cell line A549 [12]. 
The different sensitivities of the cells in the study of Kas-
telova et al to propranolol may be in part due to using differ-
ent cell types (normal and cancerous) with different origin 
(rat and human). 
  Our data along with Kastelova et al [10] revealed that 
the propranolol could show a significant cytotoxicity at rel-
atively high concentration of this drug. In Kastelova et al 
study, longer incubation time with propranolol increased its 
cytotoxicity in ≥ 0.5 mM concentration of the drug [10]. In 
our study, although propranolol cytotoxicity at 0.4 mM con-
centration was significantly higher than 0.2 mM, a signifi-
cant increase in cytotoxicity with time (48 h > 24 h > 12 h) 
only was observed at 0.2 mM concentration of the drug. This 
discrepancy between Kastelova et al and our study may be 
due to that Kastelova et al assessed propranolol cytotoxicity 
after 3 and 20 hours but in our study time intervals were 12, 
24 and 48h. Thus Kastelova et al started propranolol cytotox-
icity evaluation after 3h incubation which was very earlier 
than our first time interval assessment (12h). In our study, 
more than 99% of the cells died at 0.4 mM concentration of 
the drug after 12h incubation and there was no significant 
difference in propranolol cytotoxicity between different in-
cubation times at 0.4 mM dose.
   However in our study, longer incubation time with pro-
pranolol, increased its cytotoxic effect at 0.2 mM concentra-
tion. Prolongation of incubation time may increase propran-
olol concentration inside the cell. Propranolol as a cationic 
amphiphilic drug can accumulate in particular sub cellular 
organs resulting in greatly higher local concentrations from 
that in the medium [20]. Accumulation of propranolol in ly-
sosomes and non specific binding of it to animal microsomes 
have been reported [21]. Furthermore repeated administra-
tion of propranolol caused cytotoxicity at lower doses com-
pared to single treatment of hepatoma cell line HBG BC2 
[22]. So continual uses of propranolol in patients, possibly, 
make it cytotoxic at lower concentrations in vivo compared 
to in vitro usage of this drug.  In addition chronic adminis-
tration of propranolol in ulcer patients resulted in a minor 
inhibitory effect on proliferation of PHA-stimulated lym-
phocytes [23]. Also in rat model, continual administration 
of propranolol strongly inhibits hepatic metabolism and has 
different effects on rat lung type II pnemocytes and alveolar 
macrophage xenobiotic metabolizing enzyme activities [24]. 
Covalent binding of metabolic intermediates of propranolol 
to some liver isoenzymes has also been reported [25]. 
 Our results along with other investigators findings sug-
gest that propranolol, in addition to its primary action on 
beta-adrenergic receptors, may modulate cellular functions 
at  higher  concentrations. We  also  evaluated  the  effect  of 
propranolol on leukemic cells in the presence of PHA. We 
did not find any difference in propranolol cytotoxicity in the 
presence or absence of PHA (data not shown). This suggests 
that PHA dependent proliferative mechanisms are also sensi-
tive to propranolol. 
 While the anti-tumoral and anti-inflammatory properties 
of propranolol on a variety of carcinomas have been shown 
by some investigators [6-9, 15-17] and its antiproliferative 
effect on some normal cells was observed in its continuing 
use [25], the cytotoxic effects of this drug on normal cells, at 
its effective anti tumoral concentration has not been reported 
yet. Accordingly it could be noteworthy to assess its cytotox-
ic effect on normal cells as well as tumor cells in a long time 
period in vivo to determine the most effective anti- tumoral 
dose of the drug with regard to lowest cytotoxic effects on 
normal body components in a special period of time.  
  As a whole our results suggest that propranolol could 
be a possible useful agent for chemoprevention of leukemic 
disorders along with its chronic long-term usage in cardiac 
problems.
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